To further investigate the antitumor efficacy of WntSI in patients with NSCLC, we established a patient‐derived xenograft (PDX) model of lung adenocarcinoma harboring EGFR mutation and MET amplification in NOD/SCID mice (Figure 7A). This evidence concerns the gene EGFR and lung adenocarcinoma.